Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antiprotozoal presented as a 250 mg atovaquone / 100 mg proguanil hydrochloride tablet for oral use. It is indicated for the prevention and treatment of malaria caused by Plasmodium falciparum in travelers and residents of endemic regions. GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured to meet European Union quality standards and is distributed across global markets. It complies with EU pharmacopoeial specifications and undergoes rigorous batch testing.

Malarone is used in the antiprotozoal therapeutic class to prevent and treat malaria infections.

- Malaria prophylaxis: prevents Plasmodium falciparum infection in travelers to endemic areas. - Acute uncomplicated malaria: treats confirmed P. falciparum malaria in non‑pregnant patients. - Chemoprophylaxis for chloroquine‑resistant malaria: provides effective protection where chloroquine resistance is prevalent.

Malarone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often reported. - Abdominal pain: discomfort in the abdomen. - Headache: transient cranial pain. - Vomiting: occasional emesis.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin and mucosal reaction. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Anaphylaxis: life‑threatening allergic response.

Before prescribing Malarone, consider the following precautions to ensure safe use.

- Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: unknown excretion; weigh infant risk versus maternal benefit. - Renal or hepatic impairment: use with caution and monitor function. - Drug resistance: ensure adherence to dosing schedule to prevent resistance. - Concomitant medications: review for potential interactions that may affect drug levels. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Malarone can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma concentrations, compromising efficacy. - Anticonvulsants (e.g., carbamazepine, phenytoin): lower atovaquone exposure, risking treatment failure. - Cimetidine: may increase atovaquone levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Azithromycin: additive risk of QT interval prolongation. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.